DRUG
Bright Minds Biosciences IncKey Statistics
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc. (DRUG) is a clinical-stage biotechnology company focused on creating innovative therapies for central nervous system disorders, targeting mental health challenges and pain management. Harnessing its proprietary drug development platform, Bright Minds is advancing a compelling pipeline of candidates designed to improve both efficacy and safety amid a growing acceptance of psychedelic therapies. With a seasoned management team and a strong intellectual property portfolio, the firm aims to capitalize on the burgeoning demand for transformative mental health solutions, positioning itself as a potential leader in the evolving pharmaceutical landscape while offering attractive prospects for institutional investors.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -27.00% |
| Return on Assets | -15.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $8.25 |
| Price-to-Book | 12.69 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $9.79M |
| Float | $6.61M |
| % Insiders | 11.58% |
| % Institutions | 67.56% |
Historical Volatility
Volatility is currently expanding